Teva is the first company to file an Abbreviated New Drug Application with the FDA for Lexapro.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) yesterday launched its generic version of Lexapro for the treatment of depression and generalized anxiety disorder. Brand Lexapro, made by Forest Laboratories inc. (NYSE: FRX), has $2.9 billion in annual US sales, according to IMS sales data.
As the first company to file an Abbreviated New Drug Application (ANDA) with paragraph IV certification with the US Food and Drug Administration (FDA) for generic Lexapro, Teva has been awarded 180-day marketing exclusivity.
Teva's share price rose 0.1% in early trading on the TASE today to NIS 165.30, after falling 1.4% on Nasdaq yesterday to $43.80, giving a market cap of $41.3 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on March 15, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012